What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Pathology, Glioma, Cancer research, Meningioma and Astrocytoma.
His Pathology research integrates issues from Fluorescence in situ hybridization, Monosomy and Gene expression profiling.
His Glioma study deals with Internal medicine intersecting with Selumetinib and Gastroenterology.
His study in Cancer research is interdisciplinary in nature, drawing from both Tumor suppressor gene, Oncogene and Mutation.
His study in the field of Benign Meningioma also crosses realms of Mitotic index.
His Astrocytoma research includes themes of ATRX and Ganglioglioma.
His most cited work include:
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. (6125 citations)
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors (938 citations)
- DNA methylation-based classification of central nervous system tumours (733 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Pathology, Meningioma, Glioma, Immunohistochemistry and Cancer research.
Arie Perry works in the field of Pathology, namely Neurofibromatosis.
His work deals with themes such as Merlin and Oncology, which intersect with Meningioma.
The various areas that Arie Perry examines in his Glioma study include Brain tumor and Internal medicine.
His Immunohistochemistry study frequently draws connections between adjacent fields such as Differential diagnosis.
His Cancer research research incorporates themes from Mutation and Tumor suppressor gene.
He most often published in these fields:
- Pathology (57.81%)
- Meningioma (15.98%)
- Glioma (15.98%)
What were the highlights of his more recent work (between 2016-2021)?
- Pathology (57.81%)
- Meningioma (15.98%)
- Internal medicine (11.31%)
In recent papers he was focusing on the following fields of study:
Arie Perry focuses on Pathology, Meningioma, Internal medicine, Oncology and Cancer research.
His Pathology research is multidisciplinary, incorporating elements of Astrocytoma, Glioma and Magnetic resonance imaging.
His Meningioma study combines topics from a wide range of disciplines, such as Transcriptome, Local failure and Proportional hazards model.
As part of one scientific family, Arie Perry deals mainly with the area of Oncology, narrowing it down to issues related to the ATRX, and often CDKN2A.
His Cancer research study incorporates themes from Mutation, Missense mutation and Epigenetics.
Arie Perry has researched Mutation in several fields, including DNA methylation and Exon.
Between 2016 and 2021, his most popular works were:
- DNA methylation-based classification of central nervous system tumours (733 citations)
- Primary brain tumours in adults. (252 citations)
- cIMPACT-NOW Update 3: Recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (228 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Arie Perry spends much of his time researching Pathology, Meningioma, Internal medicine, Glioma and Oncology.
Arie Perry connects Pathology with Extramural in his research.
Arie Perry interconnects Local failure, Resection, Recursive partitioning and Nomogram in the investigation of issues within Meningioma.
The Internal medicine study combines topics in areas such as Gastroenterology, Anaplastic astrocytoma and Selumetinib.
His Glioma research incorporates elements of Not Otherwise Specified, IDH1 R132H and Psychoanalysis.
His Oncology research is multidisciplinary, incorporating perspectives in Diffuse Astrocytoma, Clinical trial, Retrospective cohort study and ATRX.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
